Introduction We developed a clinically relevant in vivo animal model of large, wide-neck aneurysm morphologies to study aneurysms with traditionaly-high recanalization rates (up to 70% recurrence) post-treatment. This model will be treated with a new liquid embolic device under development: NeuroCURE (Aneuvas Technologies, Inc. (ATI), Flagstaff, AZ). NeuroCURE® is delivered using dual-microcatheter techniques (device delivery behind temporary balloon/stent protection). NeuroCURE is an elastic gel material that can completely fill and stabilize aneurysms long-term, potentially reducing the recanalization risk of larger aneurysms. High recanalization rates of current endovascular devices can be partially attributed to inadequate modeling of larger aneurysms during preliminary device testing in animal models, resulting in incomplete data sets prior to device approval.
Materials and Methods The large animal model was developed in canines by the Neurosurgery Research Center at Barrow Neurological Institute (BNI) and ATI. Both swine and canines exhibit adequate blood-flow, blood pressure, and vessel size to accommodate larger aneurysm models and dual microcatheter techniques - which are not feasible in the current rabbit-elastase models. Canines have been adopted over swine because they exhibit a healing response comparable to humans. Swine exhibit an overly-aggressive clotting cascade.A lateral wall aneurysm was surgically created by anastomosis of an external jugular vein (EJV) segment onto the common carotid artery (RCCA) in the neck. The EJV segment was sewn along circular sidewall cuts (5 – 7 mm diameter) in the RCCA to form a wide-neck aneurysm. The distal EJV was tied off at a dome height >10 mm. The animals were survived at least 2 weeks pre-embolization.
Results Angiographic imaging verified the model forms into a patent aneurysm with large dome and wide-neck morphologies (<2:1 midline-dome:neck (D:N) ratio - figure 1A). Histology verifies healing of the aneurysm neck (re-established endothelial layer). The 2-week survival prior to device treatment allows for differentiation of the model versus the device healing response for short- and long-term studies.
Conclusion By building upon previous animal modeling experiences with rabbit, swine, and canine, we are able to develop a specific model for the simulation of endovascular techniques and device deployment in large aneurysm morphologies. This model is currently being used to test the liquid embolic, NeuroCURE®. The model has been approved by the Food and Drug Administration (FDA) for NeuroCURE assessment, with the goal of reducing large aneurysm recurrence rates in patients.
Disclosures T. Becker: 1; C; NIH STTR Phase II (2R42NS097069-02A1). 2; C; Aneuvas Technologies, Inc. 4; C; Aneuvas Technologies, Inc. 6; C; Aneuvas Technologies, Inc. W. Merritt: 2; C; Aneuvas Technologies, Inc. C. Settanni: 1; C; IH STTR Phase II (2R42NS097069-02A1). N. Norris: 1; C; IH STTR Phase II (2R42NS097069-02A1). A. Ducruet: 1; C; IH STTR Phase II (2R42NS097069-02A1). 4; C; Aneuvas Technologies, Inc. M. Preul: 1; C; NIH STTR Phase II (2R42NS097069-02A1). 4; C; Aneuvas Technologies, Inc.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.